Analystreport

SpringWorks Therapeutics (NASDAQ: SWTX) had its "overweight" rating re-affirmed by analysts at Barclays PLC. They now have a $55.00 price target on the stock, up previously from $52.00.

SpringWorks Therapeutics, Inc. - common stock  (SWTX) 
Last springworks therapeutics, inc. - common stock earnings: 3/12 04:30 pm Check Earnings Report